Portfolio company Bionyra Pharma dosed first healthy volunteers in a Phase 1 study of BYN-001, a long-acting IL-25 antibody for atopic dermatitis.
Bionyra is a biotechnology company focused on developing new biologics to treat immune diseases, including inflammatory bowel disease and atopic dermatitis
Bionyra is a biotechnology company focused on developing new biologics to treat immune diseases, including inflammatory bowel disease and atopic dermatitis.